Meeting the NICE requirements: A markov model approach

Value in Health

Volumn 3, Issue 4, 2000, Pages 287-293

  Mauskopf, Josephine ^a  

^a RTI INTERNATIONAL   (United States)

Author keywords

Aggregate benefits; Aggregate costs; Cost utility analysis; Markov model; National Health Service; National Institute of Clinical Excellence (NICE)

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEALTH CARE; HEALTH SERVICE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MODEL; PRIORITY JOURNAL; UNITED KINGDOM;

EID: 0033793345     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2000.34006.x     Document Type: Article

References (17)

1. Prevalence based economic evaluation
2. Forecasting coronary heart disease incidence, mortality, and cost: The coronary heart disease policy model
3. Stroke treatment economic model (STEM): Predicting long-term costs from functional status
4. Modeling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection
5. The cost-effectiveness of treatment with lamivudine and zidovudine compared to zidovudine alone: A comparison of Markov model and trial data estimates
6. Combination antiretroviral therapy in HIV infection: An economic perspective
7. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs
8. The lifetime cost of treating a person with HIV
9. 3
10. Cost-effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ cell counts less than 300/ul in 5 European countries
11. Changing use of hospital services and costs at a London AIDS referral centre, 1983-1989
12. The incidence and prevalence of AIDS and prevalence of other severe HIV disease in England and Wales for 1995 to 1999: Projections using data to the end of 1994
13. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
14. Several classes of new drugs emerging for Parkinson's disease